NIVF

NewGenIvf Group Limited
CAPPED RATING

NewGenIvf Group Limited (NIVF) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Momentum (F). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B+
Factor Score 3.5 / 5.0
Growth
B+
Factor Score 3.8 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
F
Factor Score 0.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.3
Rev Growth YoY -4.7%
Gross Margin 23.9%
Price Return 3M -99.5%
Price Return 12M -100.0%
Catalyst Signal 0.00
Market Cap $442.2K
TTM Revenue $4.6M
Price / Sales 0.1
ROE 5.5%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B+ (3.5) B+ (3.8) B (3.2) F (0.3) C+ (2.6) C+ (2.7)
2026-11-06 B+ (3.5) B+ (3.8) B (3.2) F (0.2) C+ (2.7) C+ (2.7)
2026-10-30 B+ (3.5) B+ (3.8) B (3.3) F (0.3) C+ (2.7) C+ (2.7)
2026-10-23 B+ (3.5) B+ (3.8) B (3.3) F (0.3) C+ (2.6) C+ (2.7)
2026-10-16 B (3.5) B+ (3.8) B (3.3) F (0.3) C+ (2.6) C+ (2.7)
Page 1 of 4